XNAS · Healthcare · Medical Care Facilities
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | Q1 2026 | -0.34 | -0.30 | +11.76% | $0 | ✅ Beat | +1.81% | -0.82% | — |
| 2026-03-24 | Q4 2025 | -0.40 | -0.59 | -47.50% | $0 | ❌ Miss | +1.12% | +5.94% | +75.29% |
| 2025-11-04 |
| Q3 2025 |
| -0.40 |
| -0.38 |
| +5.00% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-07-31 | Q2 2025 | -0.38 | -0.41 | -7.89% | $0 | ❌ Miss | +3.30% | -0.92% | +1.61% |
| 2025-02-27 | Q4 2024 | -0.62 | -0.63 | -1.61% | $0 | ❌ Miss | +0.26% | +2.55% | -27.04% |
| 2024-10-31 | Q3 2024 | -0.57 | -0.56 | +1.75% | $0 | ✅ Beat | -0.21% | +11.34% | -5.67% |
| 2024-08-01 | Q2 2024 | -0.53 | -0.56 | -5.66% | $0 | ❌ Miss | +2.33% | +1.74% | +5.01% |
| 2024-05-08 | Q1 2024 | -0.49 | -0.55 | -12.24% | $0 | ❌ Miss | +0.47% | -2.59% | -18.35% |
Showing last 8 quarters.